CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 1.62×, higher than 95% of its Biotechnology peers (median 0.07×)
- FinancialsAltman Z-Score 0.43: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
596.77MGBP791.76M · vs all stocks (USD)
Revenue (TTM)
168.74MGBP223.88M · vs all stocks (USD)
Profit Margin
-17.85%vs Biotechnology peers
Beta
1.09xvs all stocks
52-Week Change
-17.18%vs all stocks
Market Capitalization
596.77MGBP791.76M · vs all stocks (USD)
Enterprise Value
612.73MGBP812.93M · vs all stocks (USD)
Forward P/E
-80.11xvs Biotechnology peers
Price to Sales (TTM)
3.54xvs Biotechnology peers
Price to Book (MRQ)
6.52xvs Biotechnology peers
Enterprise to Revenue
3.63xvs Biotechnology peers
Enterprise to EBITDA
-33.55xvs Biotechnology peers
Profit Margin
-17.85%vs Biotechnology peers
Operating Margin
-7.88%vs Biotechnology peers
Return on Assets (TTM)
-6.98%vs Biotechnology peers
Return on Equity (TTM)
-40.37%vs Biotechnology peers
Revenue (TTM)
168.74MGBP223.88M · vs all stocks (USD)
Revenue per Share (TTM)
1.51GBPUpdated Sep 23, 2026Quarterly Revenue Growth
22.50%vs Biotechnology peers
Gross Profit (TTM)
65.98MGBP87.54M · vs all stocks (USD)
EBITDA (TTM)
-18.26MGBP-24.23M · vs all stocks (USD)
Net Income (TTM)
-30.13MGBP-39.97M · vs all stocks (USD)
Operating Cash Flow (TTM)
507.00KGBP672.66K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-13.25KGBP-17.58K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00GBPFY2025 · Dec 31, 2025Revenue
168.74MGBPFY2025 · Dec 31, 2025Cost of Goods Sold
102.76MGBPFY2025 · Dec 31, 2025Gross Profit
65.98MGBPFY2025 · Dec 31, 2025Operating Income
-32.96MGBP-43.73M · vs all stocks (USD)
Pre-tax Income
-31.94MGBPFY2025 · Dec 31, 2025Income Tax Expense
-1.29MGBPFY2025 · Dec 31, 2025Net Income
-30.64MGBPFY2025 · Dec 31, 2025EBIT
-17.43MGBPFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.37MGBPFY2025 · Dec 31, 2025Research & Development
5.06MGBPFY2025 · Dec 31, 2025Selling, General & Administrative
36.76MGBPFY2025 · Dec 31, 2025Other Operating Expenses
57.70MGBPFY2025 · Dec 31, 2025Non-operating Interest Income
5.18MGBPFY2025 · Dec 31, 2025Non-operating Interest Expense
14.50MGBPFY2025 · Dec 31, 2025EPS (Basic)
-26.92GBPFY2025 · Dec 31, 2025EPS (Diluted)
-26.92GBPFY2025 · Dec 31, 2025Basic Shares Outstanding
111.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
111.92MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
517.00KGBPFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00GBPFY2025 · Dec 31, 2025Operating Cash Flow
-33.05MGBPFY2025 · Dec 31, 2025Free Cash Flow
-37.81MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.88MGBPFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-31.94MGBPFY2025 · Dec 31, 2025Stock-based Compensation
4.68MGBPFY2025 · Dec 31, 2025Other Non-cash Items
-465.00KGBPFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.66MGBPFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
16.33MGBPFY2025 · Dec 31, 2025Capital Expenditures
-4.76MGBPFY2025 · Dec 31, 2025Net Acquisitions
-3.34MGBPFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.10MGBPFY2025 · Dec 31, 2025Long-term Debt Issuance
41.95MGBPFY2025 · Dec 31, 2025Long-term Debt Payments
-38.77MGBPFY2025 · Dec 31, 2025Other Financing Charges
-2.00MGBPFY2025 · Dec 31, 2025Net Financing Cash Flow
59.24MGBPFY2025 · Dec 31, 2025Shares Outstanding
120.75MSharesUpdated Sep 23, 2026Float Shares
60.64MSharesUpdated Sep 23, 2026% Held by Insiders
20.55%vs all stocks
% Held by Institutions
66.82%vs all stocks
Total Cash (MRQ)
96.90MGBP128.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8020GBPUpdated Sep 23, 2026Total Debt (MRQ)
148.13MGBP196.53M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.62xvs Biotechnology peers
Current Ratio (MRQ)
2.20xvs Biotechnology peers
Book Value per Share (MRQ)
0.7560GBPUpdated Sep 23, 2026Total Assets
325.72MGBP432.15M · vs all stocks (USD)
Total Current Assets
185.65MGBPFY2025 · Dec 31, 2025Total Liabilities
234.37MGBPFY2025 · Dec 31, 2025Total Non-current Assets
140.07MGBPFY2025 · Dec 31, 2025Total Non-current Liabilities
150.15MGBPFY2025 · Dec 31, 2025Total Current Liabilities
84.22MGBPFY2025 · Dec 31, 2025Cash
96.88MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents
96.88MGBPFY2025 · Dec 31, 2025Accounts Receivable
22.69MGBPFY2025 · Dec 31, 2025Inventory
17.33MGBPFY2025 · Dec 31, 2025Accounts Payable
14.21MGBPFY2025 · Dec 31, 2025Short-term Debt
6.06MGBPFY2025 · Dec 31, 2025Long-term Debt
142.07MGBPFY2025 · Dec 31, 2025Common Stock (Book)
60.38MGBPFY2025 · Dec 31, 2025Retained Earnings
-422.35MGBPFY2025 · Dec 31, 2025Total Shareholders' Equity
91.35MGBP121.19M · vs all stocks (USD)
52-Week Low
420.00GBXUpdated Sep 23, 202652-Week High
962.00GBXUpdated Sep 23, 202652-Week Change
-17.18%vs all stocks
Beta
1.09xvs all stocks
50-Day MA
519.01GBXUpdated Sep 23, 2026200-Day MA
624.76GBXUpdated Sep 23, 2026Avg 10-Day Volume
700.54KSharesUpdated Sep 23, 2026Avg 30-Day Volume
793.69KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
-0.2700GBPUpdated Sep 23, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.62×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.62Industry median: 0.07Industry P95: 0.93Peers compared: 260
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 128,566,055.25Total Debt (USD): 196,528,824Debt-to-Equity: 1.62
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.20Altman Z-Score: 0.43
Financial Health
Altman Z-Score 0.43: distress zoneCritical
Altman Z-Score: 0.43
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Suning.com Co., Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Lianchuang Electronic Technology Co. Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Sunward Intelligent Equipment Co., Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone